LAMP1 and chronic myelogenous leukemia, BCR-ABL1 positive: The analysis of the possible effect of age on NK cells from TKI-treated CML patients shows a lower expression of activation markers NKp44 and CD69 in elderly compared with middle-aged TKI-treated CML patients whereas no significant differences related with age are found in the other parameters studied, including CD107a expression and IFN-γ production in K562 stimulated NK cells from TKI-treated CML patients (Figure 6D), indicating that age is not a limitation of the NK cell recovery after treatment with TKI.